The Effect of LymphaTouch® and Manual Lymphatic Drainage on Extremity Circumference Measurements in Lymphedema

November 16, 2025 updated by: Istanbul Physical Medicine Rehabilitation Training and Research Hospital

The Effect of LymphaTouch® and Manual Lymphatic Drainage on Extremity Circumference Measurements in Lymphedema: A Retrospective Study

This retrospective study will be conducted using the medical records of lymphedema patients followed in the Physical Medicine and Rehabilitation outpatient clinics and lymphedema unit of Istanbul Physical Medicine and Rehabilitation Training and Research Hospital. Women and men aged 18-75 years with a diagnosis of upper or lower extremity lymphedema will be included. Sociodemographic and clinical data of the patients will be recorded, and participants will be divided into two treatment groups: those who received LymphaTouch® therapy and those who underwent Manual Lymphatic Drainage (MLD). Pre- and post-treatment extremity circumference measurements will be obtained from patient records, and the differences between the groups will be compared.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

172

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Istanbul, Turkey (Türkiye)
        • Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

ChatGPT:

The study population consists of patients with lymphedema who received either LymphaTouch® or Manual Lymphatic Drainage (MLD) treatment.

Description

Inclusion Criteria:

  • Clinically diagnosed with lymphedema
  • Aged between 18 and 75 years
  • Complete pre- and post-treatment extremity circumference measurements available in patient records

Exclusion Criteria:

  • History of systemic diseases such as diabetes, rheumatologic disorders, or malignancy
  • Presence of neurological disorders (e.g., polyneuropathy, multiple sclerosis, history of stroke)
  • Pregnancy
  • History of surgery or major trauma involving the affected limb within the past 6 months
  • History of injection therapy or physical therapy applied to the same limb within the past 6 months
  • History of infection or active dermatological disease affecting the limb
  • Incomplete or inconsistent data in patient records

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MLD group
Patients with lympedema who received MLD treatment
Other: No intervention
No intervention
Lymphatouch group
Patients with lympedema who received Lymphatouch treatment
Other: No intervention
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Extremity Circumference (cm):
Time Frame: Baseline
he primary outcome will be the difference in limb circumference measurements before and after treatment. Circumference values will be obtained from standardized anatomical landmarks, including the wrist/ankle, and at 10 cm, 20 cm, 30 cm, and 40 cm proximal to the metatarsophalangeal (MTP) or metacarpophalangeal (MCP) joint. A greater reduction in circumference indicates a more effective treatment response.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2025

Primary Completion (Actual)

October 10, 2025

Study Completion (Actual)

November 10, 2025

Study Registration Dates

First Submitted

November 16, 2025

First Submitted That Met QC Criteria

November 16, 2025

First Posted (Actual)

November 20, 2025

Study Record Updates

Last Update Posted (Actual)

November 20, 2025

Last Update Submitted That Met QC Criteria

November 16, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • istftreah2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe